Evidence map›Paper›PMID 28264462›Full record

ArticleInternational journal of environmental research and public health2017

Use of the QuantiFERON-TB Gold In-Tube Test in the Diagnosis and Monitoring of Treatment Efficacy in Active Pulmonary Tuberculosis.

Ping-Chin Chang, Pin-Hui Wang, Kow-Tong Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Capturing RecentTropical medicine and infectious disease · 2024
    Article
  2. Bode Phase Angle Signaling of a TB Disease Biomarker.Molecules (Basel, Switzerland) · 2023
    Article
  3. Article
  4. Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ping-Chin ChangDivision of Infectious Diseases, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan 736, Taiwan. 2LH101@TMH.org.tw.
Pin-Hui WangDepartment of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan. e8755013@yahoo.com.tw.
Kow-Tong ChenDepartment of Public Health, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan. ktchen@mail.ncku.edu.tw.
Chi Mei Medical Center · TWNational Cheng Kung University · TWTainan Municipal Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The value of QuantiFERON in the diagnosis of tuberculosis disease and in the monitoring of the response to anti-tuberculosis treatment is unclear. The aims of this study were to evaluate the accuracy of the QuantiFERON-TB Gold In-Tube (QFT-GIT) test in the diagnosis of tuberculosis and in the monitoring of the response to anti-tuberculosis treatment in patients with active pulmonary tuberculosis (PTB). Between January 2013 and December 2015, 133 cases with active PTB and 133 controls with no mycobacterial infection, matched by age (within 3 years) and by the week that they visited Tainan Chest Hospital, were enrolled in the study. Serial testing by QFT-GIT at baseline and after 2 and 6 months of treatment was performed. At these time points, a comparison of the performance of QFT-GIT with that of sputum culture status among study subjects was conducted. Compared to baseline, 116 (87.2%) cases showed a decreased response, whereas 17 (12.8%) showed persistent or stronger interferon-gamma (IFN-γ) responses at 2 months. PTB patients IFN-γ responses declined significantly from baseline to 2 months (median, 6.32 vs. 4.12;

Indexed as

Reagent Kits, DiagnosticAgedAntitubercular AgentsBiological AssayFemaleGoldHumansInterferon-gammaMaleMiddle AgedSensitivity and SpecificitySputumTreatment OutcomeTuberculosis, PulmonaryAntitubercular AgentsGoldInterferon-gammaReagent Kits, Diagnosticpulmonary tuberculosisQuantiFERON-TB Gold In-Tube testsensitivityspecificity

Identifiers

PMID28264462
PMCPMC5369072
OpenAlexW2577685819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.